Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis

doi:10.5306/wjco.v15.i8.1092

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (53)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=50

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Aug 24, 2024 (publication date) through Aug 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Oncol. Aug 24, 2024; 15(8): 1092-1101
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1092

Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis

Ji Li, Hao Zhang, Xiao-Dong Chen

Ji Li, Hao Zhang, Xiao-Dong Chen, Department of General Surgery, Chongqing Western Hospital, Chongqing 400051, China

Co-first authors: Ji Li and Hao Zhang.

Author contributions: Li J and Zhang H conceived and designed the study; Chen XD and Zhang H collected data and performed the database search; Li J and Zhang H performed statistical analysis; Li J, Zhang H, Chen XD drafted the manuscript; Li J and Chen XD confirm the authenticity of all the raw data; All authors revised the manuscript; All authors have read and approved the final manuscript.

Conflict-of-interest statement: All authors declare that they have no competing interests.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Dong Chen, MS, Doctor, Master's Student, Department of General Surgery, Chongqing Western Hospital, No. 301 Huafu Road, Jiulongpo, Chongqing 400051, China. 236165437@qq.com

Received: June 23, 2024
Revised: July 18, 2024
Accepted: July 24, 2024
Published online: August 24, 2024
Processing time: 53 Days and 18.6 Hours

Core Tip

Core Tip: The current therapeutic drugs have limited effectiveness in treating secondary mutations in different gastrointestinal stromal tumor (GIST), and new treatment strategies need to be developed. Ripretinib (RPT) is a new, switch-control tyrosine kinase inhibitors that can suppress different mutations of KIT and PDGFRA via a dual mechanism of action. This study aims to investigate the literature on RPT to assess an effective, safe, and successful treatment strategy against advanced GIST.